- Home
- YETI vs EWTX Comparison
YETI vs EWTX Comparison
Compare YETI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YETI | EWTX |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | YETI | EWTX |
|---|---|---|
| Price | $47.93 | $30.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $41.92 | $34.71 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 02-19-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $1,831,326,000.00 | N/A |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $24.93 | ★ N/A |
| Revenue Growth | ★ 1.56 | N/A |
| 52 Week Low | $26.61 | $10.60 |
| 52 Week High | $51.29 | $31.29 |
Technical Indicators
Market Signals| Indicator | YETI | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 60.94 |
| Support Level | $46.38 | $29.30 |
| Resistance Level | $49.22 | $31.26 |
| Average True Range (ATR) | 1.47 | 1.58 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 66.91 | 89.44 |
Price Performance
Historical ComparisonAbout YETI YETI Holdings Inc.
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.